Sharyn D Baker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8646935/publications.pdf

Version: 2024-02-01

206	11,408	19657 61	33894 99
papers	citations	h-index	g-index

210	210	210	12655
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 242-252.	21.4	588
2	CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature, 2011, 471, 235-239.	27.8	542
3	Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clinical Cancer Research, 2007, 13, 3731-3737.	7.0	283
4	Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001. Journal of the National Cancer Institute, 2002, 94, 1883-1888.	6.3	249
5	An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors. Cancer Research, 2004, 64, 9139-9143.	0.9	242
6	Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. Journal of the National Cancer Institute, 2006, 98, 1739-1742.	6.3	232
7	Interaction of Imatinib with Human Organic Ion Carriers. Clinical Cancer Research, 2008, 14, 3141-3148.	7.0	207
8	Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Molecular Cancer Therapeutics, 2002, 1, 545-52.	4.1	197
9	Irinotecan pathway genotype analysis to predict pharmacokinetics. Clinical Cancer Research, 2003, 9, 3246-53.	7.0	189
10	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biology and Therapy, 2007, 6, 432-438.	3.4	177
11	A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemotherapy and Pharmacology, 1999, 44, 372-380.	2.3	163
12	Crenolanib is active against models of drug-resistant FLT3-ITDâ˜positive acute myeloid leukemia. Blood, 2013, 122, 3607-3615.	1.4	159
13	Pharmacogenetic Pathway Analysis of Docetaxel Elimination. Clinical Pharmacology and Therapeutics, 2009, 85, 155-163.	4.7	148
14	Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters. Clinical Cancer Research, 2009, 15, 6062-6069.	7.0	146
15	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 343-356.	16.8	145
16	Clinical Pharmacokinetics of Docetaxel. Clinical Pharmacokinetics, 2006, 45, 235-252.	3.5	143
17	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. Journal of Clinical Oncology, 2011, 29, 3293-3300.	1.6	142
18	Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese. Journal of Clinical Oncology, 2007, 25, 4707-4713.	1.6	141

#	Article	IF	Citations
19	Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.. Journal of Clinical Oncology, 1996, 14, 3074-3084.	1.6	138
20	Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.. Journal of Clinical Oncology, 1996, 14, 3085-3096.	1.6	129
21	Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide. Clinical Cancer Research, 2013, 19, 1458-1466.	7.0	128
22	Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemotherapy and Pharmacology, 1995, 37, 195-202.	2.3	127
23	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clinical Pharmacology and Therapeutics, 2006, 80, 192-201.	4.7	126
24	Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients. Clinical Cancer Research, 2004, 10, 8341-8350.	7.0	119
25	Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology, 1999, 17, 2604-2604.	1.6	116
26	Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan. Clinical Cancer Research, 2005, 11, 7800-7806.	7.0	115
27	Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel. Clinical Cancer Research, 2004, 10, 1976-1983.	7.0	112
28	Pharmacology of Cancer Chemotherapy in the Older Person. Clinics in Geriatric Medicine, 1997, 13, 169-183.	2.6	111
29	Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clinical Pharmacology and Therapeutics, 2004, 75, 448-454.	4.7	111
30	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications, 2019, 10, 244.	12.8	111
31	Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Clinical Cancer Research, 2007, 13, 7394-7400.	7.0	107
32	Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly. Journal of Clinical Oncology, 2005, 23, 1070-1077.	1.6	106
33	Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function. Journal of Clinical Oncology, 2006, 24, 552-562.	1.6	104
34	Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors. Journal of Clinical Oncology, 2008, 26, 5504-5510.	1.6	104
35	CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. Journal of the National Cancer Institute, 2006, 98, 1714-1723.	6.3	102
36	Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs. Clinical Cancer Research, 2007, 13, 2488-2495.	7.0	100

#	Article	IF	Citations
37	A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7, 10880.	12.8	100
38	Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies. Journal of Clinical Oncology, 2005, 23, 3906-3911.	1.6	98
39	A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia, 2010, 24, 1437-1444.	7.2	95
40	Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia. Journal of Clinical Oncology, 2001, 19, 762-771.	1.6	94
41	Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.. Journal of Clinical Oncology, 1994, 12, 1946-1954.	1.6	92
42	Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clinical Pharmacology and Therapeutics, 2003, 74, 364-371.	4.7	91
43	Tumor targeting by conjugation of DHA to paclitaxel. Journal of Controlled Release, 2001, 74, 233-236.	9.9	90
44	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITDâ€“Positive Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 5758-5768.	7.0	87
45	Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 4562-4567.	1.6	85
46	Ductal Access for Prevention and Therapy of Mammary Tumors. Cancer Research, 2006, 66, 638-645.	0.9	84
47	Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2013, 19, 3050-3058.	7.0	82
48	A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2009, 15, 6241-6249.	7.0	80
49	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research, 2012, 18, 4433-4440.	7.0	80
50	Relationship of systemic exposure to unbound docetaxel and neutropenia. Clinical Pharmacology and Therapeutics, 2005, 77, 43-53.	4.7	79
51	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. PLoS ONE, 2013, 8, e79106.	2.5	76
52	Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study. Neuro-Oncology, 2005, 7, 177-182.	1.2	75
53	Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Analytical Biochemistry, 2004, 324, 276-284.	2.4	74
54	Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia. Journal of Clinical Oncology, 2002, 20, 656-664.	1.6	73

#	Article	IF	Citations
55	Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients. Clinical Cancer Research, 2006, 12, 6100-6105.	7.0	72
56	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Investigational New Drugs, 2006, 24, 291-297.	2.6	70
57	Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil. Journal of Clinical Oncology, 2000, 18, 915-915.	1.6	69
58	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.. Journal of Clinical Oncology, 1996, 14, 1504-1511.	1.6	67
59	Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 1999, 17, 1095-1095.	1.6	65
60	Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients. Clinical Cancer Research, 2005, 11, 7398-7404.	7.0	64
61	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Research, 2013, 19, 236-246.	7.0	64
62	Pharmacodynamic-Guided Modified Continuous Reassessment Methodâ€“Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors. Journal of Clinical Oncology, 2008, 26, 4172-4179.	1.6	63
63	Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. British Journal of Cancer, 2012, 107, 1100-1106.	6.4	63
64	Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 793, 413-420.	2.3	61
65	Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 73-80.	2.3	61
66	Quantification of sunitinib in human plasma by high-performance liquid chromatographyâ€“tandem mass spectrometryâ˜†. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 874, 84-88.	2.3	60
67	Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clinical Cancer Research, 2003, 9, 3589-97.	7.0	60
68	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 2015, 75, 2729-2736.	0.9	59
69	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. Journal of Clinical Oncology, 2009, 27, 4986-4993.	1.6	57
70	A phase 1 study of the CXCR4 antagonist plerixafor in combination with highâ€dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigatorsâ€™ Consortium study (POE 10â€03). Pediatric Blood and Cancer, 2017, 64, e26414.	1.5	57
71	Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.. Clinical Cancer Research, 2006, 12, 1270-1275.	7.0	56
72	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia, 2020, 34, 735-745.	7.2	56

#	Article	IF	Citations
73	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics, 2012, 11, 921-929.	4.1	54
74	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). Clinical Cancer Research, 2014, 20, 985-994.	7.0	54
75	Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials. Journal of Clinical Oncology, 2000, 18, 2459-2467.	1.6	53
76	Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry. Steroids, 2004, 69, 721-726.	1.8	52
77	Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes. Clinical Pharmacology and Therapeutics, 2008, 84, 704-709.	4.7	52
78	A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clinical Cancer Research, 2005, 11, 664-71.	7.0	51
79	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. Journal of the National Cancer Institute, 2011, 103, 893-905.	6.3	50
80	Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib. Clinical Pharmacology and Therapeutics, 2008, 83, 477-484.	4.7	49
81	Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology, 2000, 18, 4086-4097.	1.6	48
82	Total and Active Rabbit Antithymocyte Globulin (rATG;ThymoglobulinÂ®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 274-278.	2.0	47
83	Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitroâ€“in vivo correlations. British Journal of Cancer, 2014, 110, 894-898.	6.4	47
84	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 846, 1-7.	2.3	46
85	Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3033-3038.	2.3	46
86	Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. Clinical Pharmacology and Therapeutics, 2008, 84, 111-118.	4.7	45
87	Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemotherapy and Pharmacology, 2011, 67, 695-703.	2.3	45
88	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular Cancer Therapeutics, 2008, 7, 1110-1120.	4.1	43
89	Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clinical Cancer Research, 2003, 9, 151-9.	7.0	42
90	Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer. Clinical Cancer Research, 2006, 12, 536-542.	7.0	41

#	Article	IF	Citations
91	Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243.	2.3	41
92	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Research, 2017, 77, 2102-2111.	0.9	41
93	Ontogeny and Sorafenib Metabolism. Clinical Cancer Research, 2012, 18, 5788-5795.	7.0	40
94	Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib. Clinical Cancer Research, 2013, 19, 4359-4370.	7.0	40
95	Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 773, 183-190.	2.3	39
96	Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 813, 81-88.	2.3	39
97	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. Journal of Clinical Investigation, 2017, 128, 369-380.	8.2	39
98	Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Cancer Chemotherapy and Pharmacology, 2016, 77, 1039-1052.	2.3	38
99	Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry, 1995, 19, 134-145.	1.8	37
100	Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism. Clinical Pharmacology and Therapeutics, 2011, 89, 693-701.	4.7	36
101	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. Cancer Research, 2016, 76, 117-126.	0.9	36
102	Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.. Journal of Clinical Oncology, 1998, 16, 2770-2779.	1.6	35
103	Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 61, 423-433.	2.3	35
104	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy. Clinical Cancer Research, 2012, 18, 4425-4432.	7.0	34
105	A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nature Communications, 2020, 11, 1924.	12.8	34
106	Paclitaxel Repackaged in an Albumin-Stabilized Nanoparticle: Handy or Just a Dandy?. Journal of Clinical Oncology, 2005, 23, 7765-7767.	1.6	33
107	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	33
108	Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 2959-2965.	1.6	31

#	Article	IF	Citations
109	Pharmacokinetic Considerations for New Targeted Therapies. Clinical Pharmacology and Therapeutics, 2009, 85, 208-211.	4.7	31
110	Troxacitabine, an l-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology, 2002, 20, 96-109.	1.6	30
111	Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. British Journal of Cancer, 2008, 98, 1630-1632.	6.4	28
112	OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition. Clinical Pharmacology and Therapeutics, 2012, 92, 642-650.	4.7	28
113	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Investigational New Drugs, 2020, 38, 340-349.	2.6	28
114	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics, 2011, 12, 327-339.	1.3	27
115	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clinical Pharmacology and Therapeutics, 2016, 99, 651-660.	4.7	27
116	Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITDâ€“Positive AML. Molecular Cancer Therapeutics, 2021, 20, 2207-2217.	4.1	27
117	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	12.8	26
118	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metabolism and Disposition, 2020, 48, 420-426.	3.3	26
119	Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study. Pharmacotherapy, 2004, 24, 16-25.	2.6	25
120	A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. Annals of Oncology, 1998, 9, 101-104.	1.2	24
121	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. Clinical Pharmacology and Therapeutics, 2020, 107, 227-237.	4.7	23
122	Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics, 2020, 12, 856.	4.5	22
123	Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days. Journal of Clinical Oncology, 2002, 20, 2567-2574.	1.6	21
124	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discovery, 2021, 2, 586-599.	5.0	21
125	Phase II Evaluation of Docetaxel Plus Exisulind in Patients With Androgen Independent Prostate Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 395-398.	1.3	20
126	Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients. Clinical Cancer Research, 2008, 14, 2102-2110.	7.0	20

#	Article	IF	Citations
127	Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors. Clinical Pharmacology and Therapeutics, 2013, 93, 215-219.	4.7	20
128	Boosting the oral bioavailability of anticancer drugs through intentional drugâ€“drug interactions. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 23-35.	2.5	20
129	Pharmacology of fluorinated pyrimidines: eniluracil. , 2000, 18, 373-381.		19
130	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leukemia Research, 2011, 35, 87-94.	0.8	19
131	Limited cerebrospinal fluid penetration of docetaxel. Anti-Cancer Drugs, 2004, 15, 715-718.	1.4	17
132	A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Investigational New Drugs, 2006, 24, 499-508.	2.6	17
133	Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biology and Therapy, 2007, 6, 891-897.	3.4	17
134	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1090, 43-51.	2.3	16
135	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 8.	17.0	16
136	DNA Methylationâ€Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clinical and Translational Science, 2021, 14, 137-142.	3.1	16
137	Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney International, 2021, 100, 1214-1226.	5.2	16
138	Determination of fraction unbound docetaxel using microequilibrium dialysis. Analytical Biochemistry, 2004, 331, 192-194.	2.4	15
139	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Research and Treatment, 2011, 127, 153-162.	2.5	15
140	E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. Leukemia, 2017, 31, 502-505.	7.2	15
141	A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 784-787.	2.8	14
142	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research, 2019, 25, 7320-7330.	7.0	14
143	TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI Insight, 2020, 5, .	5.0	14
144	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research, 2022, 28, 3242-3247.	7.0	14

#	Article	IF	Citations
145	Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue. Clinical Cancer Research, 2006, 12, 2158-2165.	7.0	12
146	Stability of Sunitinib in Oral Suspension. Annals of Pharmacotherapy, 2008, 42, 962-966.	1.9	12
147	Kinase Inhibitors: The Reality Behind the Success. Clinical Pharmacology and Therapeutics, 2017, 102, 726-730.	4.7	12
148	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3â€ITD AML. Clinical and Translational Science, 2019, 12, 641-647.	3.1	12
149	Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1152, 122176.	2.3	12
150	Characterization of Topotecan-Mediated Redistribution of DNA Topoisomerase I by Digital Imaging Microscopy. Experimental Cell Research, 1998, 241, 332-339.	2.6	11
151	Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. Clinical Pharmacology and Therapeutics, 2003, 74, 509-510.	4.7	11
152	Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. Analytical Biochemistry, 2005, 337, 143-148.	2.4	11
153	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational New Drugs, 2011, 29, 1057-1065.	2.6	11
154	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	4.1	11
155	In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. Clinical Cancer Research, 2005, 11, 8503-8511.	7.0	10
156	Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorganic and Medicinal Chemistry, 2016, 24, 5855-5860.	3.0	10
157	Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. Pharmacology Research and Perspectives, 2019, 7, e00534.	2.4	10
158	Determination of fraction unbound docetaxel using microequilibrium dialysis. Analytical Biochemistry, 2004, 331, 192-194.	2.4	10
159	High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: A phase II and pharmacodynamic study. Annals of Oncology, 1998, 9, 173-180.	1.2	9
160	Alternative formulations of sorafenib for use in children. Pediatric Blood and Cancer, 2013, 60, 1642-1646.	1.5	9
161	Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega, 2017, 2, 1985-2009.	3.5	9
162	Interaction Between Sex and Organic Anionâ€Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenibâ€Nâ€Oxide and Regorafenibâ€Glucuronide in Mice. Clinical and Translational Science, 2019, 12, 400-407.	3.1	9

#	Article	IF	Citations
163	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics, 2020, 12, 788.	4.5	9
164	Distribution of paclitaxel in plasma and cerebrospinal fluid. Anti-Cancer Drugs, 2003, 14, 365-368.	1.4	8
165	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 253-260.	2.8	7
166	Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Investigational New Drugs, 2007, 25, 237-245.	2.6	7
167	Clinical significance ofin vivocytarabine-induced gene expression signature in AML. Leukemia and Lymphoma, 2016, 57, 909-920.	1.3	7
168	Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination. Pharmaceutics, 2022, 14, 694.	4.5	7
169	Predicting Vinorelbine Disposition and Toxicity: Does BSA Provide More Than a â€œBad Statistical Associationâ€?. Journal of Clinical Oncology, 2006, 24, 2412-2413.	1.6	6
170	Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. Blood, 2015, 126, 3695-3695.	1.4	6
171	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer Research Communications, 2021, 1, 79-89.	1.7	6
172	A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2003, 33, 725-733.	2.8	5
173	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leukemia and Lymphoma, 2017, 58, 247-250.	1.3	5
174	A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 751-756.	2.8	4
175	Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia. Blood Advances, 2021, 5, 5041-5046.	5.2	4
176	A method for determination of dimethyl benzoylphenyl urea(BPU) in human plasma by using LC/UV. Biomedical Chromatography, 2004, 18, 282-287.	1.7	3
177	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. European Journal of Cancer, 2007, 43, 78-86.	2.8	3
178	Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. Annals of Oncology, 2008, 19, 374-379.	1.2	3
179	Pharmacokinetic Studies in Early Anticancer Drug Development. , 2011, , 189-214.		3
180	Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122882.	2.3	3

#	Article	IF	Citations
181	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. Blood, 2010, 116, 1073-1073.	1.4	3
182	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. Blood, 2016, 128, 3937-3937.	1.4	3
183	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. Blood, 2009, 114, 114-114.	1.4	3
184	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clinical Cancer Research, 2022, 28, 2536-2546.	7.0	3
185	Phase I Trial of Paclitaxel and Etoposide for Recurrent Ovarian Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 609-613.	1.3	2
186	Troxacitabine in Patients With Refractory Leukemia. Journal of Clinical Oncology, 2002, 20, 3356-3357.	1.6	2
187	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 828, 41-54.	2.3	2
188	Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.. Blood, 2005, 106, 2792-2792.	1.4	2
189	Chemotherapy in the Pediatric Patient. , 2009, , 173-207.		2
190	Reply to J. Gligorov et al. Journal of Clinical Oncology, 2011, 29, e456-e457.	1.6	1
191	Preclinical Characterization of TPâ€0903, a Novel Multikinase Inhibitor, in TP53 Mutant Acute Myeloid Leukemia. FASEB Journal, 2021, 35, .	0.5	1
192	Interaction of the FLT3 Inhibitor Gilteritinib with Xenobiotic Uptake Transporters. FASEB Journal, 2021, 35, .	0.5	1
193	Hypoxia Reporter Element Assay. Bio-protocol, 2018, 8, .	0.4	1
194	Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS. Blood, 2013, 122, 2680-2680.	1.4	1
195	High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML. Blood, 2021, 138, 207-207.	1.4	1
196	Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 4202-4202.	1.4	0
197	Gene Expression Profiling of Acute Myeloid Leukemia Shows Therapeutically Meaningful Patterns of Association with Ara-CTP Pharmacokinetics and Pharmacodynamics. Blood, 2008, 112, 215-215.	1.4	0
198	Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.. Blood, 2008, 112, 1630-1630.	1.4	0

#	Article	IF	Citations
199	Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment.. Blood, 2009, 114, 1734-1734.	1.4	0
200	Recommendation of dose banding of cytotoxics according to pharmacokinetic criteria.. Journal of Clinical Oncology, 2012, 30, 2549-2549.	1.6	0
201	TAK1 is a Regulator of Sorafenibâ€induced Keratinocyte Toxicity. FASEB Journal, 2013, 27, 657.1.	0.5	0
202	Genetic variations in cytarabine pathway genes as determinants of outcome in acute myeloid leukemia.. Journal of Clinical Oncology, 2013, 31, 10005-10005.	1.6	0
203	Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3620-3620.	1.4	0
204	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. Blood, 2016, 128, 2838-2838.	1.4	0
205	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
206	Epigenetic Regulation of OCTN1â€mediated Cytarabine Transport in Acute Myeloid Leukemia. FASEB Journal, 2019, 33, 675.2.	0.5	0